4-hydroxy-N-demethyltamoxifen,
4-hydroxy-N-desmethyltamoxifen,
4-hydroxy-N-desmethyltamoxifen, (Z)-isomer,
endoxifen,
Z-endoxifen,
Endoxifen,
112093-28-4,
Z-Endoxifen,
4-Hydroxy-N-desmethyltamoxifen,
(E/Z)-Endoxifen,
Endoxifen Z-Isomer,
UNII-46AF8680RC,
N-Desmethyl-4-hydroxytamoxifen,
110025-28-0,
4-Hydroxy-N-desmethyl-tamoxifen,
CHEBI:80555,
46AF8680RC,
4OHNDtam,
W-200834,
N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture),
(Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer),
4-hydroxy-N-desmethyltamoxifen, (Z)-isomer,
(Z)-Endoxifen,
Endoxifen(E/Z=1:1),
4-hydroxy-N-desmethyl tamoxifen,
CHEMBL1093458,
SCHEMBL10107920,
GTPL10203,
DTXSID80149880,
EX-A645,
MHJBZVSGOZTKRH-IZHYLOQSSA-N,
114828-90-9,
BCP15866,
EX-A1970,
BDBM50435003,
HY-18719E,
MFCD09840374,
NSC746494,
NSC749798,
ZINC22056306,
ACN-053042,
NSC-746494,
NSC-749798,
(E/Z)-N-desmethyl-4-hydroxy Tamoxifen,
NCGC00386714-01,
B7481,
CS-0028594,
X5886,
C16547,
(Z)-4-Hydroxy-N-Desmethyl Tamoxifen (Endoxifen),
N-Desmethyl-4-hydroxytamoxifen, mixture of isomers,
4-Hydroxy-N-Desmethyl Tamoxifen ((E/Z)-Endoxifen),
J-002363,
4-[1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol,
(E/Z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol,
(Z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol,
(Z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol,
4-[(~{Z})-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol,
4-[1-[4-[2-(METHYLAMINO)ETHOXY]PHENYL]-2-PHENYL-1-BUTENYL]PHENOL,
N-Desmethyl-4-hydroxytamoxifen, mixture of isomers, analytical standard,
4-[(1Z)-1-[4-[2-(Methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]phenol,
4-[(1Z)-1-{4-[2-(methylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol,
N-Methyl-2-[4-[(E)-1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenoxy]ethanamine,
Phenol, 4-(1-(4-(2-(methylamino)ethoxy]phenyl)-2-phenyl-1-butenyl)-, (Z)-,
Racemic Endoxifen,
4-Hydroxy-N-demethyltamoxifen,
D0W4EB,
C25H27NO2,
C25-H27-N-O2,
CID10090750,
Endoxifen (topical formulation, cancer),
C055492,
(Z)-4-Hydroxy-N-desmethyl Tamoxifen (mixture of isomers),
Endoxifen (topical formulation, cancer), Jina Pharmaceuticals,
Tamoxifen metabolite (topical formulation, cancer), Jina Pharmaceuticals,
phenol, 4-((1Z)-1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenyl-1-buten-1-yl)-,
Phenol, 4-[(1Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-,